Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study.
Teresa Mary MacDonaldChuong TranTu'uhevaha J Kaitu'u-LinoShaun P BrenneckeRichard J HiscockLisa HuiKirsten M DaneAnna L MiddletonPing CannonSusan P WalkerStephen TongPublished in: BMC pregnancy and childbirth (2018)
Plasma PlGF at 36 weeks' gestation is significantly lower in women who subsequently deliver a SGA infant. While the sensitivity and specificity of PlGF currently limit clinical translation, our findings support a blood-based biomarker approach to detect late-onset fetal growth restriction. Thirty-six week sFlt-1:PlGF ratio predicts 69.2% of preeclampsia cases, and could be a useful screening test to triage antenatal surveillance.
Keyphrases
- gestational age
- late onset
- tyrosine kinase
- early onset
- growth factor
- preterm birth
- birth weight
- epidermal growth factor receptor
- pregnancy outcomes
- pregnant women
- emergency department
- polycystic ovary syndrome
- public health
- clinical trial
- metabolic syndrome
- skeletal muscle
- study protocol
- cervical cancer screening
- physical activity